London, United Kingdom, July 03, 2019 --(PR.com)-- SMi Group reports: After the launch of Rocklatan in the USA, Aerie Pharmaceuticals will be discussing plans for a European approval at the Ophthalmic Drugs conference this November.

Last month Aerie Pharmaceuticals announced that they had received approval from the FDA for Rocklatan, the once a day eye drop designed specifically for patients with open-angle glaucoma, reducing IOP elevation*, making them the first company to get to market with this innovative product. The drug has been released in the US with plans being made for a European approval.

At SMi�s 3rd annual Ophthalmic Drugs conference, taking place in London on 18th -20th November 2019, Mitchell de Long, Vice President of Chemistry from Aerie Pharmaceuticals will discuss the launch of Rocklatan in the USA, with a focus on drug development and more specifically the ROCK inhibitor class of drugs. He will share his experiences on gaining the first FDA approval for a PG combination product and discuss the future landscape for Glaucoma treatment.

Following Mitchell�s presentation on Tuesday 19th November, Naj Sharif, Vice President of Global Ophthalmology at Santen Inc USA, will continue in a similar vein where he will focus on novel treatment modalities for managing ocular hypertension and Glaucoma.

Mitchell and Naj will also be chairing the Conference on both Day One and Day Two.

The brochure with the full programme and speaker line-up is available online.

*Glaucoma.org/news

Ophthalmic Drugs
Conference: 19th-20th November 2019
Focus Day: 18th November 2019
Copthorne Tara Hotel, London, UK
#OphthalmicDrugs
Ophthalmic Drugs 2019 is proudly sponsored by Experimentica and ProMed Pharma.

For exclusive tailored sponsorship/table-top opportunities contact: Alia Malick on +44 (0)20 7827 6168 or email [email protected]

For media enquiries contact Neill Howard on Tel: +44 (0)20 7827 6164 / Email: [email protected]